• Vaccine Ontology ID: VO_0011546
• Type: Subunit vaccine
• Status: Research
• collagen binding, ancillary pilus subunit Cne gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001324
• Immunization Route: Intranasally

• Vaccine Ontology ID: VO_0011544
• Type: Subunit vaccine
• Status: Research
• binding protein Eag gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Fnz gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Sfs gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001272
  • Description: The adjuvant used was EtxB, a recombinant form of the B subunit of Escherichia coli heat-labile enterotoxin (Flock et al., 2004).
• Immunization Route: Subcutaneously

• Vaccine Ontology ID: VO_0002798
• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• vicK gene engineering:
  • Type: Gene mutation
  • Description: This vicK mutant is from Streptococcus equi (Liu et al., 2008).
  • Detailed Gene Information: Click Here.
• Immunization Route: intranasal immunization

Mouse Response

• Host Strain: NMRI mice
• Vaccination Protocol: Fifteen to twenty microgram of each antigen and 10 μg of the adjuvant in a total volume of 12–16 μl were given to the mice by placing the antigens onto the nares and allowing the mice to inhale. This was done at three occasions at 1-week intervals. In each experiment, control animals were given only adjuvant at the same concentration omitting the antigen (Flock et al., 2006).
• Challenge Protocol: A dose containing 10⁶ CFU in a 10-μl volume was used for infection of mice (Flock et al., 2006).
• Efficacy: Mice immunized with recombinant CNE lost less weight and had less nasal colonization than the unvaccinated controls (Flock et al., 2006).

Mouse Response

• Vaccination Protocol: Mice were immunized either subcutaneously (s.c.) or intranasally (i.n.). For each antigen (FNZ, SFS, and EAG), 12 μg of antigen was mixed with an equal amount of EtxB so that all components achieved a final concentration of 300 μg/ml. In the case of i.n. immunization, the total volume was kept to less than 40 μl and applied into the nostrils of anaesthetized mice . For both s.c. and i.n. immunizations, four doses were given with 1-week intervals (Flock et al., 2004).
• Challenge Protocol: Challenge i.n. with S. equi subsp. equi (10⁶ CFU in a 10-μl volume) was given 1 week after the last booster dose (Flock et al., 2004).
• Efficacy: It was shown that nasal colonization of S. equi subsp. equi and weight loss due to infection were significantly reduced after vaccination compared with a mock-vaccinated control group. This effect was more pronounced after intranasal vaccination than after subcutaneous vaccination; nearly complete eradication of nasal colonization was obtained after intranasal vaccination (P < 0.001) (Flock et al., 2004).
• Host IgA response
  • Description: An analysis of the bronchoalveolar lavage (BAL) fluid taken after the last immunization revealed significant IgA levels to EAG in the animals immunized with the three antigens and the EtxB adjuvant. By contrast, mice immunized with the three S. equi antigens in the absence of EtxB gave significantly lower IgA responses (Flock et al., 2004).
  • Detailed Gene Information: Click Here.

Mouse Response

• Persistence: A vicK mutant is attenuated in mice (Liu et al., 2008).
• Efficacy: A vicK mutant induces protection in mice from challenge with wild type S. equi (Liu et al., 2008).